Zooming in on the implantable telescope

Article

A long-term Phase II/III study (IMT002) of an implantable telescope prosthesis for end-stage macular degeneration has demonstrated that it can improve quality of life and sustain visual acuity (VA) improvements.

A long-term Phase II/III study (IMT002) of an implantable telescope prosthesis for end-stage macular degeneration has demonstrated that it can improve quality of life and sustain visual acuity (VA) improvements, according to Mark Packer, one of the trial investigators from the USA.

The prospective, observational clinical trial enrolled 206 subjects across 28 US centres. Patients were over 55 years of age (mean age 76 years) with bilateral central scotomas due to untreatable age-related macular degeneration (AMD). Exclusion criteria included evidence or treatment of active choroidal neovascularization (CNV) in the preceding six months, diabetic retinopathy, history of retinal detachment, endothelial cell density <1,600 cells/mm2 and previous intraocular or corneal surgery.

Mean best corrected visual acuity (BCVA) at baseline was 20/312. At two years, mean BCVA had improved by 3.2 lines, within three letters of one year BCVA. A gain of more than three lines of distance BCVA was observed in 59.2% of implanted eyes, compared with 10.3% of fellow eye controls (p<0.0001).

The National Eye Institute Visual Function Questionnaire (NEI VFQ) scores, at one year, demonstrated relevant VFQ subscales improved from seven to 14 points. Mean endothelial cell density decreased by 20% at three months, 25.3% at one year and an additional 2.5% in year two. Two cases of corneal decompensation were recorded during year one, while none were seen in year two.

This pivotal study is the first to demonstrate that the implantable telescope can improve and sustain VA as well as improving quality of life.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.